Investors fret as new regulatory probes spur fresh delays to Roche's $4.3B Spark buyout
Another day, another delay. On Monday, Roche revealed that in addition to the US Federal Trade Commission, the UK’s Competition and Markets Authority is probing the Spark Therapeutics takeover deal, triggering another delay of the $4.3 billion acquisition announced in February.
Spark shareholders now have until July 31 to tender their shares.
Since its last update in mid-May, the percentage of shares already sold inched up to 21.1% from 21%, lower than 26.1% and 29.4% registered on previous deadlines. These numbers are still a far cry from the 50% required to consummate the deal, but Roche has maintained it’s not unusual for “a significant portion of shareholders” to wait until the last days of the offer period.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.